AMOEBA (EPA:ALMIB) - AMOEBA: publication of a new paper in the scientific journal « Pathogens »

Transparency directive : regulatory news

20/10/2021 14:56

PRESS RELEASE

  AMOEBA: publication of a new paper in the scientific journal " Pathogens "

  Absence of intracellular multiplication of seven legionella strains in the
                      amoeba Willaertia magna C2c Maky.

Chassieu (France), October 20, 2021 - AMOEBA (FR0011051598 - ALMIB), producer
of a biological biocide capable of eliminating bacterial risk in water and
human wounds, and of a biocontrol product for plant protection, still in the
testing phase, announces the publication in Pathogens, the international
high-impact peer-reviewed scientific journal, of scientific results showing the
absence of intracellular multiplication of seven strains of legionella in the
amoeba Willaertia magna C2c Maky.

This work follows and supplements the paper jointly published in 2020 by the
Institut Hospitalo- Universitaire Méditerranée Infection in Marseille and the
company Amoéba in Chassieu (see press release of February 7, 2020). The
results of this new study have just been published in the special issue
"Classic and Non-classic Intracellular Bacteria: Host immunity and Microbial
Persistence Strategies" of Pathogens, that covers topics related to pathogens
and pathogen-host interactions. The published and peer-reviewed paper reports
the efficacy of the amoeba Willaertia magna C2c Maky in ingesting and
eliminating seven strains of Legionella non-pneumophila
(https://www.mdpi.com/2076-0817/10/10/1350/pdf).

Some amoebae, widely distributed in the environment such as Acanthamoeba
castellanii, are known to multiply Legionella. Amoeba showed in 2020 that this
phenomenon did not occur in Willaertia magna C2c Maky with three strains of
Legionella pneumophila. However, there are more than 60 species of Legionella,
some of which can also cause outbreaks of Legionellosis. It was therefore
essential to verify with representative strains that Willaertia magna C2c Maky
was able to eliminate them.

Confirmation of the ability of Willaertia magna C2c Maky to ingest and
eliminate legionella

Results demonstrate that Willaertia magna C2c Maky is also resistant to other
species of Legionella. This property was evaluated in parallel for two other
amoebae, known to be permissive. On the one hand, the data corroborate the
multiplicative capacity of certain Legionella in Acanthamoeba castellanii and
in an amoeba of the same species as Willaertia magna C2c Maky, the amoeba
Willaertia magna T5(S)44. On the other hand, these results confirm the ability
of Willaertia magna C2c Maky to ingest and eliminate legionella.

The authors studied 7 Legionella non-pneumophila strains belonging to the
species L. longbeachae, L. anisa, L. bozemanae, L. taurinensis, and L.
dumoffii, some of which were responsible for legionellosis epidemics. As
temperature can influence amoebic behavior, a temperature range (between 22°C
and 37°C) that can be encountered in cooling water from cooling towers was
used.

* At 22°C: the three amoebae were able to phagocytose the seven bacterial
  strains and prevent their intracellular multiplication except for
  L. longbeachae which multiplied in Willaertia magna T5(S)44.

* At 37°C: four bacterial strains were able to hijack the cellular machinery
  of one or two amoebae, but in nether of Willaertia magna C2c Maky.

"These results confirm that Willaertia magna C2c Maky has unique properties and
is an excellent candidate to become the first biological biocide for the
treatment of water in cooling towers," says Sandrine DEMANECHE, Chief
Scientific Officer at Amoéba.

As a reminder, the evaluation of the regulatory dossier for approval of the
biocidal active substance Willaertia magna C2c Maky for use in cooling towers
in Europe is under review by the Member State rapporteur, with an end of
evaluation scheduled for the end of 2021, before shifting to the European level
for review by the European Chemicals Agency (ECHA).

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-nature.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,
" Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts: Amoéba
Valérie FILIATRE Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 12, 2021 under number
D21-0289 (a copy of which is available on www.amoeba-nature.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 341 109,20 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA: publication of a new paper in the scientific journal « Pathogens »

Transparency directive : regulatory news

AMOEBA's latest news

Other stories